Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis - Report - MDSpire

Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis

  • By

  • Miloš Grujić

  • Marija Živković Radojević

  • Tinatin Alaverdashvili

  • Imdat Eroglu

  • Katarina Krasić

  • Katarina Janković

  • Neda Milosavljević

  • June 23, 2026

  • 0 min

Share

Clinical Report: Inflammatory and Epigenetic Adaptations in Prostate Cancer

Background

Prostate cancer is a significant health issue, with treatment resistance contributing to disease progression and mortality. Androgen deprivation therapy (ADT) is a critical component of management, yet many tumors adapt through various mechanisms, including alterations in androgen receptor (AR) signaling. Understanding the interplay between endocrine therapy and radioresistance is essential.

Data Highlights

No numerical data or trial data were provided in the source material.

Key Findings

  • Endocrine therapy may initially impair AR-dependent DNA damage response signaling.
  • Sustained endocrine pressure can lead to adaptive inflammatory signaling and epigenetic remodeling.
  • Adaptive inflammatory activation may reduce radiosensitization in prostate cancer.
  • Serial biomarker profiling during endocrine exposure and radiotherapy may better identify emerging resistance than baseline assessments.
  • The proposed model suggests a dynamic biologic state of radiosensitization that evolves over time.

Clinical Implications

Monitoring inflammatory markers and epigenetic changes may provide insights into treatment resistance.

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities
  2. npj Digital Medicine, 2025 -- Combining Single-Cell and Spatial Transcriptomics with Explainable AI Uncovers Critical Prognostic Factors in Prostate Cancer
  3. Frontiers in Oncology, 2026 -- Editorial: Epigenetic modulation in cancer
  4. EAU - EANM - ESTRO - Guidelines on Prostate Cancer, 2026
  5. Archives of Toxicology — Overcoming Drug Resistance in Cancer through EMT: Innovative Treatment Approaches
  6. Mixed results with enzalutamide in non-metastatic prostate cancer
  7. EAU - EANM - ESTRO -
  8. Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions - PMC

Original Source(s)

Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis

  • by Miloš Grujić, Marija Živković Radojević, Tinatin Alaverdashvili, Imdat Eroglu, Katarina Krasić, Katarina Janković, Neda Milosavljević

  • June 23, 2026

Related Content

Radiomics-based interpretable machine learning model from multiphasic CT imaging for predicting pathological grade in upper tract urothelial carcinoma: a multicenter study

Liquid Biopsy in Pediatric Acute Lymphoblastic Leukemia (ALL)

Efficacy of Jishi Shuanghua Granules in preventing radiation-induced esophagitis in non-small cell lung cancer patients undergoing concurrent chemoradiotherapy: protocol for a multicenter, randomized, double-blind, placebo-controlled trial